Immuno-Oncology

The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

Rajni Natesan, MD, MBA | Image credit: Clarified Precision Medicine
Bringing the Human Factor to the “Last Mile” of AI-Assisted Clinical Decisions

May 24th 2024

This article will appear in the June 2024 issue of Evidence-Based Oncology.

Doctor with health care icons and FDA | Image credit: wladimir1804 - stock.adobe.com
Tarlatamab Receives Accelerated Approval for Extensive-Stage SCLC

May 17th 2024

Lung cancer diagnosis concept | Image Credit: VitaliiVodolazskyi-stock.adobe.com
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial

May 16th 2024

U.S. Food and Drug Administration FDA approved | Calin - stock.adobe.com
FDA Grants Accelerated Approval for Liso-Cel for R/R Follicular Lymphoma

May 16th 2024

Keytruda packaging | Image credit: Merck
Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer

May 9th 2024

More News

CAR T image
July 25th 2022

Fungal Infections Rarer, Linked With Worse Prognosis in Patients Receiving CAR T-Cell Therapy

Jaime Rosenberg
Overall, infections occurred in 18.42% of cases and typically occurred within the first month, significantly dropping from then on.
Melissa L. Johnson, MD
July 22nd 2022

Dosing Study of Modakafusp Alfa Shows Promise in Solid Tumors; Tests Planned With Checkpoint Inhibitors

Mary Caffrey
Manish Patel, MD
July 22nd 2022

Lucitanib With Nivolumab Sees Responses in Gynecological Cancer Treatment

Mary Caffrey
Frederick L. Locke, MD
July 22nd 2022

Data Indicate Lower Response Rates to Axi-cel Among Black Patients

Mary Caffrey
ASCO Spotlight With Kim A. Reiss, MD, on CAR Macrophages and Other Developments in Pancreatic Cancer
July 21st 2022

ASCO Spotlight With Kim A. Reiss, MD, on CAR Macrophages and Other Developments in Pancreatic Cancer

Maggie L. Shaw Hayley Virgil
Kim A. Reiss, MD, assistant program director, assistant professor of medicine, Hospital of the University of Pennsylvania, Philadelphia, discusses 2 abstracts presented during ASCO.
Inspection Delays Prompt FDA Deferral on Tislelizumab in Second-line ESCC
July 14th 2022

Inspection Delays Prompt FDA Deferral on Tislelizumab in Second-line ESCC

Mary Caffrey
Nicolas K. Trad
July 7th 2022

Patients With Cancer Face Major Financial Roadblocks, Not All Concerning Out-of-Pocket Costs

Maggie L. Shaw
Abstracts presented at this year's American Society of Clinical Oncology Annual meeting detailed the financial hardships many patients with cancer face, including those related to high-deductible health plans and clinical trial participation.
Zahra Mahmoudjafari, PharmD, BCOP
July 2nd 2022

Dr Zahra Mahmoudjafari Explains How Payers Can Better Manage CAR T Costs, Increase Access

Skylar Jeremias Lindsey Mulrooney
Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, explains some of the strategies that payers can use to improve cost management and increase patient access related to chimeric antigen receptor T-cell (CAR T) therapies.
Zahra Mahmoudjafari, PharmD, BCOP
June 23rd 2022

Dr Zahra Mahmoudjafari Previews CAR T Therapies Coming Down the Pipeline

Skylar Jeremias Lindsey Mulrooney
Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, catalogues the chimeric antigen receptor T-cell (CAR T) therapies that are coming down the pipeline.
COTA’s Miruna Sasu on Real-world Evidence: “The Ecosystem Has Changed”
June 23rd 2022

COTA’s Miruna Sasu on Real-world Evidence: “The Ecosystem Has Changed”

Mary Caffrey
Miruna Sasu, PhD, MBA, became president and CEO of COTA Healthcare in March 2022, not quite a year after joining the company as its chief strategy officer. As the importance of RWD grows, Sasu is ready to take its use in precision oncology to new levels. She spoke with Evidence-Based Oncology™ (EBO) about her new role.
Image of a broken heart
June 17th 2022

Major Adverse Cardiac Events Related to ICI Treatment Explored in New Study

Rose McNulty
Major adverse cardiac events are rare but serious in patients treated with immune checkpoint inhibitors (ICIs), and increased awareness is crucial to identify and treat these conditions in a timely manner.
Blood samples in tubes
June 15th 2022

Exploring the Landscape of Current Immune Checkpoint Inhibitors

Rose McNulty
Immune checkpoint inhibitors have changed the way certain cancers are treated, but more can be done to optimize treatment and improve patient responses.
cancer cells
June 13th 2022

Review Highlights Potential for CLDN18.2 as a Therapeutic Target in Various Cancers

Rose McNulty
While no agents are approved just yet, a variety of promising drugs targeting CLDN18.2 are undergoing early research and clinical trials for several cancer types. 
Aklilu Tedla, Cardinal Health
June 8th 2022

Cardinal Health’s Aklilu Tedla on CAR T-Cell Administration Outside of the Hospital

Moving chimeric antigen receptor (CAR) T-cell therapies outside of the hospital will bring training and safety challenges, said Aklilu Tedla, vice president, insights and engagement, regulatory science, cell and gene, Cardinal Health.
Aklilu Tedla, Cardinal Health
May 31st 2022

Cardinal Health’s Aklilu Tedla Discusses Logistics of Allogeneic CAR T-Cell Therapies

Allogeneic, or off-the-shelf, chimeric antigen receptor (CAR) T-cell therapies will bring new logistical challenges, said Aklilu Tedla, vice president, insights and engagement, regulatory science, cell and gene, Cardinal Health.
Joel Wayment of Cardinal Health
May 24th 2022

Joel Wayment Discusses the Logistical Challenges of CAR T-Cell Distribution and Storage

The logistics for storing chimeric antigen receptor (CAR) T-cell therapies remain a challenge, said Joel Wayment, vice president of operations for 3PL Services, Cardinal Health.
cancer cells
May 20th 2022

Review Highlights Tumor Microenvironment Features Contributing to Immunotherapy Resistance

Rose McNulty
Treatment resistance is a significant challenge in immunotherapy, but it is not fully understood. A recent review summarized 5 tumor microenvironment traits that may inhibit therapy effectiveness and potential strategies to improve therapy responses.
Miruna Sasu, PhD, MBA, COTA Healthcare
May 18th 2022

Dr Miruna Sasu Discusses the Transformative Power of Real-world Data

Mary Caffrey Maggie L. Shaw
Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, discusses the medicines discovery process and how real-world data can be used to evaluate patient and tumor response to treatment regimens.
CAR T image
May 10th 2022

Pressure-Induced Increase in PD-L1 Expression May Dull Effect of CAR T-Cell Therapy

Jaime Rosenberg
The study of constructed αROR1‐CAR T cells showed an increase of PD-L1 expression when exposed to elevated pressure, driving resistance to CAR T cell-mediated cytotoxicity. However, the findings also suggest that adding PD-1/PD-L1 inhibitors to CAR T-cell therapy could help address this.
Image of medical research
May 7th 2022

Researchers Call for Better Detection of, Intervention for AEs From PD‐1/PD‐L1 Treatment

Jaime Rosenberg
The researchers highlighted a need for the detection of more relevant markers and guidance on how to treat adverse events (AEs), the types and severity of which vary based on disease type.
Moffitt Team Finds Potential CAR T Target for Solid Tumors
May 5th 2022

Moffitt Team Finds Potential CAR T Target for Solid Tumors

AJMC Staff
So far, the wonders of chimeric antigen receptor (CAR) T-cell therapy have only been seen in blood cancers. Investigators at Moffitt Cancer Center report findings that show a potential target in solid tumors.
Review Highlights Progress and Potential in Immunotherapy Plus Radiotherapy for Cancer Treatment
April 26th 2022

Review Highlights Progress and Potential in Immunotherapy Plus Radiotherapy for Cancer Treatment

Rose McNulty
With further research, a selection of combination therapies could increase patient response in various cancer types.
NCCN Recommends Pacritinib for Treatment of Myeloproliferative Neoplasms
April 18th 2022

NCCN Recommends Pacritinib for Treatment of Myeloproliferative Neoplasms

Julia Bonavitacola
Pacritinib is now included as a recommended treatment for myeloproliferative neoplasms with specificity for JAK2 and IRAK1 in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines.
Evidence, Support, and Education Needed to Drive Precision Oncology, Accenture’s Bogdan Says
April 14th 2022

Evidence, Support, and Education Needed to Drive Precision Oncology, Accenture’s Bogdan Says

Mary Caffrey
Accenture’s 2021 report, “The Future Is Now: How to Drive Precision Oncology Adoption," adds to the chorus calling for greater sharing of data and improved standardization, so that academic centers and community practices alike can continually improve data sets used worldwide.
Camille Hertzka, AstraZeneca
April 12th 2022

AstraZeneca’s Camille Hertzka Addresses rPFS in mCRPC

Mary Caffrey Maggie L. Shaw
Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, clarifies testing for the HRR mutation in metastatic castrate-resistant prostate cancer (mCRPC) and the predictive importance of radiographic progression-free survival (rPFS) for overall survival in this setting.
Study Finds LCOR May Be a Viable Target to Increase Efficacy of Immunotherapy in TNBC
April 8th 2022

Study Finds LCOR May Be a Viable Target to Increase Efficacy of Immunotherapy in TNBC

Rose McNulty
Therapy resistance remains a challenge with immune checkpoint inhibitors, and a new study proposes targeting ligand-dependent corepressor (LCOR) in addition to known immune targets to improve outcomes.
graphic depicting immunotherapy response
April 4th 2022

Study Identifies Potential Blood-Based Biomarkers for PD-1 Inhibitor Response in Advanced Small Bowel Cancer

Rose McNulty
Immune checkpoint inhibitors have changed the treatment landscape of certain cancer types, and a recent study aims to provide new insight on why treatment response varies so much from patient to patient.
FDA Approves Axi-cel in Second Line for LBCL, Expands CAR T Pool by 11,000 in US Alone
April 1st 2022

FDA Approves Axi-cel in Second Line for LBCL, Expands CAR T Pool by 11,000 in US Alone

Mary Caffrey
The expanded use of axi-cel, sold as Yescarta, while not unexpected, nonetheless represents uncharted territory in cancer care.
Camille Hertzka, AstraZeneca
April 1st 2022

AstraZeneca’s Camille Hertzka: Olaparib Could Be Practice Changing

Mary Caffrey Maggie L. Shaw
Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why so much excitement has been generated for the use of olaparib (Lynparza) in the first line for patients with metastatic castrate-resistant prostate cancer.
Image of engineered cancer treatment
March 24th 2022

Overcoming CAR T-Cell Exhaustion Remains a Challenge, Especially in Solid Tumors

Rose McNulty
Despite progress in chimeric antigen receptor (CAR) T-cell therapy, further research is needed to fully understand and overcome CAR T-cell exhaustion and improve outcomes.
<123456789
...
14>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences™ and AJMC®.
All rights reserved.

About Us
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo